A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy.
about
Role of P-glycoprotein inhibitors in ceramide-based therapeutics for treatment of cancer.Novel delivery approaches for cancer therapeutics.Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML).Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma.Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group.Marine sponge-derived sipholane triterpenoids reverse P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cellsZosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a pBR-independent, direct transporter-modulating mechanismAfatinib reverses multidrug resistance in ovarian cancer via dually inhibiting ATP binding cassette subfamily B member 1.How will lung cancer be treated in the future?Tailor-made chemotherapy for non-small cell lung cancer patients.Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins.Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor.Pharmacokinetics of single ascending doses of the P-glycoprotein inhibitor tariquidar in healthy subjects.Therapeutic potential of RNA interference in drug-resistant cancers.Intrinsic resistance to chemotherapy in breast cancer.Investigational ABC transporter inhibitors.Pharmacogenetic considerations for non-Hodgkin's lymphoma therapy.New-generation efflux pump inhibitors.Therapeutic Potential and Utility of Elacridar with Respect to P-glycoprotein Inhibition: An Insight from the Published In Vitro, Preclinical and Clinical Studies.The molecular interaction of a copper chelate with human P-glycoprotein.Targeting P-glycoprotein: Investigation of piperine analogs for overcoming drug resistance in cancer.A newly synthesized nickel chelate can selectively target and overcome multidrug resistance in cancer through redox imbalance both in vivo and in vitro.Quantitative evaluation of the combination between cytotoxic drug and efflux transporter inhibitors based on a tumour growth inhibition model.Effects of the inhibition of intestinal P-glycoprotein on aliskiren pharmacokinetics in cynomolgus monkeys.P-glycoprotein regulates Staphylococcus aureus enterotoxin B-stimulated interleukin-5 and thymic stromal lymphopoietin secretion in organotypic mucosal explants.
P2860
Q30274798-8F418573-A41D-49C7-AAEF-03D012B9CCDCQ30368171-6525BD93-4FF4-4001-B6E0-24E9EBA7166CQ33319637-6756B7C8-FBA2-49DE-8958-DBE293B9CE76Q33490314-F7472BBD-B2A5-4071-91BD-BF59C40D6C4EQ33729158-9B91E93C-9210-46AD-969D-D9685A6D9D47Q34166391-6F763975-670C-49D7-B779-736888E41BD7Q34360283-D7BD4425-7F04-4CC3-BFD5-1B98CECEFC45Q35847659-5EC06D24-875C-4615-86D0-A7D67E6A7FB8Q36413392-811148C1-49D4-4858-903F-85D031C875C8Q36429550-FE276047-D3B2-4B3B-9D21-30F4BD4779E3Q36430761-6B913075-EA1E-4A64-8929-D08D5A52E7BAQ36525551-50D54B94-6D58-4E03-A214-7B8E8601FBF0Q36788463-4D5BA6B8-F700-46EA-9DAE-B4B58AB51DD9Q36947641-EBFBC833-FE38-41DB-BCC7-7C5CCB63AF42Q37414354-D5F6CD70-94D6-41F0-A373-D6768F4B4CABQ37813694-899BFBA2-F9A4-4E95-A7C9-D84C80AD074AQ38001734-8B495CA7-E2F5-4C91-BC10-1EBC54E2CA05Q38140118-178DBFF0-FA76-4D7B-A727-DA106C4D3A22Q38178317-076C063D-E072-4025-9BBE-2E744E7CAEE8Q38856951-4055D31D-3BB9-43FE-9325-A3887D8A3B0CQ39409956-D71CD8DA-5210-436D-99EF-5E83C4EB8374Q41368134-2C4612F1-E555-42A2-9F54-342E042C6831Q42795867-BAA48F4F-10C8-409E-80F7-705DCD904404Q43968777-E8F9658C-F22A-485C-BDD7-AF4B63DEECE6Q46163291-019230D5-7AC4-4A81-9613-7680B1784E45Q51623068-31288787-B43B-4A61-B8B5-CC22AB2939CA
P2860
A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy.
description
2004 nî lūn-bûn
@nan
2004 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
A Phase I trial of a potent P- ...... ents with advanced malignancy.
@ast
A Phase I trial of a potent P- ...... ents with advanced malignancy.
@en
type
label
A Phase I trial of a potent P- ...... ents with advanced malignancy.
@ast
A Phase I trial of a potent P- ...... ents with advanced malignancy.
@en
prefLabel
A Phase I trial of a potent P- ...... ents with advanced malignancy.
@ast
A Phase I trial of a potent P- ...... ents with advanced malignancy.
@en
P2093
P1476
A Phase I trial of a potent P- ...... ents with advanced malignancy.
@en
P2093
Ajai Chaudhary
Alan Sandler
Christopher A Slapak
Christopher Jordan
Christopher Sweeney
Dinesh P De Alwis
Isabelle Pouliquen
Karen Fife
Linda Battiato
Lisa Green
P304
P356
10.1158/1078-0432.CCR-03-0644
P407
P577
2004-05-01T00:00:00Z